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Abstract
Burkholderia pseudomallei is a Gram-negative bacterium that causes the serious human disease, melioidosis. There is no
vaccine against melioidosis and it can be fatal if not treated with a specific antibiotic regimen, which typically includes the
third-generation cephalosporin, ceftazidime (CAZ). There have been several resistance mechanisms described for B.
pseudomallei, of which the best described are amino acid changes that alter substrate specificity in the highly conserved
class A b-lactamase, PenA. In the current study, we sequenced penA from isolates sequentially derived from two melioidosis
patients with wild-type (1.5 mg/mL) and, subsequently, resistant (16 or $256 mg/mL) CAZ phenotypes. We identified two
single-nucleotide polymorphisms (SNPs) that directly increased CAZ hydrolysis. One SNP caused an amino acid substitution
(C69Y) near the active site of PenA, whereas a second novel SNP was found within the penA promoter region. In both
instances, the CAZ resistance phenotype corresponded directly with the SNP genotype. Interestingly, these SNPs appeared
after infection and under selection from CAZ chemotherapy. Through heterologous cloning and expression, and
subsequent allelic exchange in the native bacterium, we confirmed the role of penA in generating both low-level and high-
level CAZ resistance in these clinical isolates. Similar to previous studies, the amino acid substitution altered substrate
specificity to other b-lactams, suggesting a potential fitness cost associated with this mutation, a finding that could be
exploited to improve therapeutic outcomes in patients harboring CAZ resistant B. pseudomallei. Our study is the first to
functionally characterize CAZ resistance in clinical isolates of B. pseudomallei and to provide proven and clinically relevant
signatures for monitoring the development of antibiotic resistance in this important pathogen.
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Introduction
Burkholderia pseudomallei, the etiologic agent of melioidosis, is a
saprophytic bacterium that is commonly found in surface waters
and soil of Australia and Thailand. There is no effective vaccine
against melioidosis, and reducing mortality from infection is based
on effective antimicrobial therapy combined with supportive
care. B. pseudomallei has a large accessory genome [1,2] and is
intrinsically resistant to many antibiotics, including gentamicin,
streptomycin, rifampicin, erythromycin and many b-lactams [3,4].
There are several different mechanisms of antibiotic resistance in
B. pseudomallei, including multi-drug efflux pumps [5,6], enzymatic
inactivation [7,8], impermeability of the bacterial cell membrane
[9] and mutations in the antibiotic target site [10]. This impressive
array of intrinsic resistance and broad-spectrum mechanisms limits
the number of treatment options for melioidosis. Successful
treatment of melioidosis is protracted and typically involves two
stages comprising an intravenous (IV) phase followed by prolonged
oral eradication therapy [11]. In Australia, the IV drug of choice
for treating melioidosis is ceftazidime (CAZ), although the
carbapenem drugs meropenem or imipenem are used for severe
infection or in the event of treatment failure. The oral eradication
phase consists of trimethoprim-sulfamethoxazole (TMP-SMX)
(in combination with doxycycline in Thailand) or amoxicillin-
clavulanate (AMC), and is given for up to six months because of
the frequency of relapse upon termination of treatment with
shorter therapy [12]. In Thailand, CAZ is the IV antibiotic of
choice [11]. Thus, CAZ is the single most important antibiotic for
the treatment of melioidosis.
The vast majority of B. pseudomallei strains are susceptible to
CAZ, imipenem, meropenem, TMP-SMX, doxycycline and
AMC, although a small percentage of isolates display primary
resistance [4]. Of great concern to clinicians is the potential for this
bacterium to develop resistance during the course of chemother-
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resistance of B. pseudomallei to CAZ is rare, the prolonged nature of
melioidosis treatment increases the likelihood that acquired
resistance can develop, especially if monotherapy is used or if
the infection relapses and CAZ is employed multiple times in the
same patient. Such acquired resistance has important ramifica-
tions due to the high morbidity and mortality associated with this
infectious disease and the paucity of alternate treatment options.
Determining the molecular basis of CAZ resistance (CAZ
R)
ultimately provides the genetic targets needed for improved
treatment outcomes for melioidosis patients by allowing
clinicians to rapidly and inexpensively monitor the emergence
of resistant populations. It has been previously shown that
mutations in the B. pseudomallei class A b-lactamase (encoded by
the gene, penA) may confer CAZ
R [13–15]. These studies
identified mutations in the penA gene of CAZ
R strains that
caused amino acid alterations around conserved motifs. How-
ever, functional characterization of penA in clinical isolates of B.
pseudomallei has not yet been explored. Thus, there is a need to
pinpoint the precise molecular mechanisms behind CAZ
R in
clinical B. pseudomallei isolates that correlate with the CAZ
R
phenotypes observed by clinicians.
In the current study, we determined the molecular mechanisms
for CAZ
R in B. pseudomallei strains from two Australian melioidosis
patients who temporally developed resistant CAZ
R strains during
CAZ therapy. To confirm that CAZ
R developed in vivo and was
not the result of re-infection with a resistant strain, we subjected
the patient isolates to multilocus variable-number tandem repeat
analysis (MLVA) and multilocus sequence typing (MLST). In
addition, we screened a large panel of clinical and environmental
B. pseudomallei for CAZ
R mechanisms using allele-specific real-time
PCR to determine the rate of primary CAZ
R in this bacterium.
Last, we tested a panel of b-lactams to determine the suitability of
these alternate antibiotics for treating CAZ




Ethics approval was granted by the Human Research Ethics
Committee of the Northern Territory Department of Health and
the Menzies School of Health Research (HREC 04/09), with
written informed consent obtained from patients.
B. pseudomallei clinical isolates used in this study
Melioidosis ‘‘Patient 21’’. Three isolates from Patient 21
(P21) [16,17] were used for this study (Table 1). The first two
isolates were susceptible to CAZ (CAZ
S), whereas the most recent
isolate, MSHR 99, displayed CAZ
R (16 mg/mL; Table 1). P21, a
63 y.o. male with Type 2 diabetes, chronic renal disease and
hazardous alcohol use from Darwin, Australia, was diagnosed with
melioidosis following B. pseudomallei isolation from blood cultures
(isolate MSHR 73). The patient was treated with IV CAZ and
TMP-SMX for two weeks and was discharged on doxycycline.
The patient had recrudescence of disease three months later, and
B. pseudomallei was again isolated from blood cultures (MSHR 95).
Following further treatment with CAZ the patient was placed on
oral AMC, but subsequently deteriorated (MSHR 99 from blood
culture) and died 4 months after his initial admission.
Melioidosis ‘‘Patient 337’’. Six B. pseudomallei isolates
derived from an individual (P337) suffering from relapsing
melioidosis were obtained for this study. Although the earliest
two isolates obtained from this patient were CAZ
S, four latter
isolates harbored a high-level CAZ
R phenotype ($256 mg/mL;
Table 1). P337, a 61 y.o. male with Type 2 diabetes and metastatic
bronchogenic carcinoma, likely contracted melioidosis following
environmental exposure with B. pseudomallei-contaminated soil.
Upon initial admission and B. pseudomallei isolation (isolate MSHR
1141), P337 was placed on IV CAZ for four weeks, followed by
oral TMP-SMX and doxycycline. In addition to antimicrobial
therapy, the patient required immunosuppressive therapy for their
malignancy. A four-month follow-up revealed that P337 was still
culture-positive for B. pseudomallei (MSHR 1225) despite being on
oral doxycycline. Intravenous CAZ was re-administered for
three weeks followed by maintenance therapy comprising oral
doxycycline and chloramphenicol. P337 remained culture positive
for B. pseudomallei and strains isolated between five to seven months
after the initial diagnosis displayed CAZ
R (MSHR 1226 onwards).
P337 remained on oral antibiotics but succumbed to the
bronchogenic carcinoma shortly thereafter.
Bacterial growth conditions
B. pseudomallei isolates were grown on Luria-Bertani agar (LBA)
(Beckton-Dickinson, Franklin Lakes, NJ) at 37uC for 24 h to 48 h.
All Escherichia coli strains (Supplemental Table S1) including
‘‘Escherichia cloni’’ 10G (Lucigen, Middleton, WI) were grown on
LBA at 37uC for 24 h. Antibiotic susceptibility testing was
Table 1. Burkholderia pseudomallei isolates obtained from two relapsed melioidosis patients, Patient 21 and Patient 337, and their
corresponding ceftazidime MICs.
Isolate ID
a Patient Date of isolation Site of isolation CAZ
b MIC (mg/mL) penA sequence
MSHR 73 21 11-Jan-91 Blood 1.5 w.t.
MSHR 95 21 3-Apr-91 Blood 1.5 w.t.
MSHR 99 21 3-May-91 Blood 16 penA -21A
MSHR 1141 337 13-Mar-01 Sputum 1.5 w.t.
MSHR 1225 337 25-Jul-01 Throat 1.5 w.t.
MSHR 1226 337 10-Aug-01 Throat $256 penA 281A
MSHR 1298 337 09-Oct-01 Throat $256 penA -21A, 281A
MSHR 1300 337 09-Oct-01 Rectal swab $256 penA -21A, 281A
MSHR 1302 337 09-Oct-01 Unknown $256 penA -21A, 281A
aMSHR, Menzies School of Health Research;
bCAZ, ceftazidime.
doi:10.1371/journal.pone.0030789.t001
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Maria, CA) at 37uC.
Antibiotic sensitivity testing
A previous study has shown that B-lactam MIC testing in B.
pseudomallei is independent of salt concentrations [15]. Therefore,
MICs were determined solely using E-tests (bioMe ´rieux, Durham,
NC) according to the manufacturer’s instructions.
PCR amplification, sequencing and cloning of penA
PCR amplification of the Burkholderia penA gene was performed
using HotStarTaq Master Mix (Qiagen, Valencia, CA) with the
addition of betaine (Sigma Aldrich, St. Louis, MO) to a final
concentration of 1.8 M, using the following primers (59-39);
penA_F (CGCCACAAATTCGCACGCAC) and penA_R (GCG-
ACTCGCGCTCCGTGAAC) (IDT, Coralville, IA). The thermo-
cycling conditions were 95uC for 15 min followed by 35 cycles of
30 s at 95uC, 30 s at 65uC, and 1 min at 72uC, with a final
extension of 10 min at 72uC. Cloning of penA PCR products was
performed using the pGC
TM Blue Vector (Lucigen) according to
the manufacturer’s instructions. Sanger sequencing was used to
identify polymorphisms, to determine insert orientation and to
verify presence of insert. Nucleotide sequences of penA from CAZ
S
and CAZ
R B. pseudomallei isolates from P21 and P337 have been
submitted to NCBI.
Allelic exchange of penA
Allelic exchange was performed using the suicide vector
pMo130 [18], which is compliant for use with Select Agent
bacteria such as B. pseudomallei. We used this allelic exchange
system to remove penA from both CAZ
S and CAZ
R isolates,
enabling us to determine whether this single gene was responsible
for the CAZ
R. Briefly, both the upstream and downstream regions
of penA were amplified using the following respective primers (59-
39); penA_US_R (AAGCGGTCAGATCTTCCGCGTTGTGC-
TGGA) and penA_US_F (GCATATCTGCTAGCTCTGTTG-
CGGCATCGCTTT), penA_DS_R (CCGAGATCTTCACG-
GAGCGCGAGTC) and penA_DS_F (GACAAGCTTGAAAAA-
CAGGGCGAACGCACAGG). These primers amplify approxi-
mately 800–1000 bp regions flanking penA but do not amplify
the gene itself. Underlined nucleotides represent deliberately
introduced restriction enzyme (RE) sites, which are required for
ligation into pMo130. Amplification was performed using
slowdown PCR as previously described [19] without the addition
of the altered dGTP analog. Following PCR, amplicons were
purified using a PCR purification kit (Qiagen). The upstream
product was digested with NheI (Promega, Madison, WI) and BglII
(Promega), and the downstream fragment was digested with BglII
and HindIII (Promega) according to the manufacturer’s instruc-
tions. It is important to note that target amplicons did not contain
these RE sites to ensure intact, full length amplicons upon
digestion. Following digestion, products were ligated into NheI and
HindIII digested pMo130 to create pMo130-US-DS. Correct
orientation and incorporation of PCR products in the final
construct were verified by multiple RE analyses. The remaining
allelic exchange procedure was performed as previously described
[18].
Cis complementation of penA
The penA gene was reintroduced into DpenA strains according to
previously described methods [18] that are in compliance with
Select Agent Rule 42 CFR Part 73 (http://www.selectagents.gov/
Regulations.html). First, the upstream region was amplified using
the primers described previously. Following amplification, the
upstream region was digested with NheI and BglII and was
introduced into pMo130 digested with NheI and BglII to create
pMo130-US. Second, penA was amplified from MSHRs 663
(penA
+), 99 (penA minus(2)21A; 16 mg/uL CAZ
R), 1226 (penA
281A; $256 mg/uL CAZ
R) or 1300 (penA -21A, 281A; $256 mg/
uL CAZ
R) depending on the desired construct (Supplemental
Table S1). Amplification of penA was performed using the
following primers (59-39); penA_comp_F (GTTCAGCAGATC-
TAACAGATCGCCGAGATGG) and penA_comp_R (GCAC-
CGCGATATCTCGCGCTCCGTGAACCTT) with underlined
nucleotides representing deliberately introduced BglII and EcoRV
restriction sites, respectively. Third, the downstream (DS) region of
penA was amplified using the following primers; penA_DScompF
(59-CTTCCGGATATCTCACGGAGCGCGAGTC) and pe-
nA_DScompR (59-CGACGACAAGCTTGAAAAACAGGGC-
GAACGCACAGG). Underlined nucleotides represent EcoRV
and HindIII sites, respectively. Last, the amplified fragment
containing penA was digested with BglII and EcoRV and the DS
fragment was digested with EcoRV and HindIII, and both DS and
penA fragments were ligated into pMo130-US digested with BglII
and HindIII. The final construct was verified by restriction
analyses (data not shown). Importantly, the penA amplicon
included 200 bp of the penA upstream region, such that promoter
sequences were incorporated into the pMo130-US-penA-DS
vectors to ensure expression when re-introduced into B. pseudo-
mallei. Following creation, the pMo130-US-penA-DS construct was
introduced into the B. pseudomallei DpenA strains and the gene
deletion was reversed following previously published protocols
[18].
penA SNP characterization using PCR
Genomic DNA obtained from approximately 2,400 genetically
and geographically diverse Burkholderia spp. isolates (Price EP et al.,
manuscript in preparation) was used to screen for the presence of
the mutant penA 281A SNP in these isolates. These samples largely
comprise clinical and environmental Burkholderia isolates from
Australia and Thailand, but also other isolates collected from
around the world. DNA was extracted using the DNeasy tissue
extraction kit (Qiagen), 5% chelex-100 heat soak [20] or the
Wizard genomic DNA purification kit (Promega). DNA was
normalized to 1 ng/mL using the NanoDrop 8000 spectropho-
tometer (Thermo Scientific, Waltham, MA) prior to PCR analysis.
We developed a SYBR Green-based mismatch amplification
mutation assay (SYBR MAMA) protocol for interrogating the
mutant and wild-type variants at the penA -21A and penA 281A
SNPs in B. pseudomallei and Burkholderia mallei. Due to the highly
conserved nature of penA among near-neighbor Burkholderia spp.,
these assays also produce amplicons for B. oklahomensis, B.
thailandensis, B. vietnamiensis, B. humptydooensis sp. nov. and B.
ubonensis, albeit at lowered efficiency due to primer-template
mismatches. SYBR MAMA exploits the differential amplification
efficiency of allele-specific primers for SNP interrogation [21,22].
In real-time PCR, this differential efficiency is observed by
measuring the cycles to threshold (CT) of both allele-specific
primers to determine the nucleotide present at the SNP. For penA -
21A interrogation, two allele-specific primers, 21promA_99_F (59-
CACTCCTGTGACGAGAGCTGATTCA) and 21promG_wt_F
(59-CACTCCTGTGACGAGAGCTGATTCG) and one com-
mon reverse primer 21prom_comR (59-GGCGACGTTTTTC-
GCTTGG) were used to interrogate the SNP. For penA 281
primers, penA_281-G (59-GGCGACGAGCGTTTCCCGTTA-
TG) and penA_281-A (59-TTTTTTTTTTTTTTTCGACGAG-
CGTTTCCCGTTATA) were used in combination with penA_
Burkholderia pseudomallei Ceftazidime Resistance
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SNP. PenA_281-A amplifies the mutant allele, which confers an
enhanced ability to degrade CAZ, whereas penA
+ is preferentially
amplified by penA_281-G. PCRs consisted of one allele specific
primer and the appropriate reverse primer per well. All samples
were run in duplicate. A total 0.3 uM of each primer (IDT), 16
SYBR Green PCR Master Mix (Applied Biosystems, Foster City,
CA), and molecular grade water (GIBCO, Carlsbad, CA) were
added to a volume of 9 mL. One mL of DNA template was added
to the reaction. All PCRs were conducted using an ABI PRISM
7900HT real-time PCR instrument (Applied Biosystems) and
default cycling conditions that comprised 2 min at 50uC, 10 min
at 95uC, followed by 40 cycles of 15 sec at 95uC and 1 min at
60uC. A dissociation curve was performed following amplification
to confirm amplicon specificity. MSHR 1300 was used as a
positive control for the mutant alleles.
16S rDNA PCR
To verify bacterial DNA quality, we ran a control 16S PCR
against all DNA samples using previously published primers [23].
All 16S PCRs were performed on the ABI PRISM 7900HT real-
time PCR instrument (Applied Biosystems) using default cycling
conditions.
Multiple locus variable number tandem repeat analysis
(MLVA)
MLVA was performed on the P21 and P337 isolates as
previously described [24], with the exclusion of locus 20 k, to rule
out re-infection with different strains.
Multi-locus sequence typing (MLST)
MLST was performed as described elsewhere [25].
Results
Sequencing of penA from P21 and P337 isolates
We sequenced penA of B. pseudomallei isolates obtained from two
melioidosis patients (P21 and P337; Table 1; Genbank accession
numbers JQ364927 through JQ364935) where CAZ
R appeared to
have developed directly in response to CAZ chemotherapy. All
isolates from P21 (MSHRs 73, 95 and 99) demonstrated the same
PenA amino acid composition and were identical to the wild-type
PenA of CAZ
S B. pseudomallei K96243. However, analysis of the
promoter region uncovered a novel G to A nucleotide transition
(referred to herein as penA -21A) in the latter isolate, MSHR 99,
which was not present in either MSHRs 73 or 94 (Table 1) (Note
that mutation numbering was determined from the whole genome
annotation of B. pseudomallei 1106a due to the absence of penA
signal peptide annotation in B. pseudomallei K96243). Importantly,
the G to A transition corresponded to a 10-fold increase in CAZ
R
(16 mg/mL), suggesting this SNP is involved in up-regulation of
penA expression.
The majority of CAZ
R isolates from P337 also showed the same
putative regulatory mutation in the promoter region (MSHRs
1298, 1300 and 1302). In addition, we identified a mutation in
penA at position 281 in most of the latter isolates that resulted in a
cysteine to tyrosine (C69Y) substitution adjacent to the
70SXXK
73
conserved motif (Ambler’s numbering scheme) [26]. This SNP has
been previously identified in CAZ
R B. pseudomallei isolates [14],
and functionally characterized in a Select-Agent exempt strain of
B. pseudomallei [15]. The mutated penA (referred to herein as penA
281A) directly corresponded to high-level CAZ
R ($256 mg/mL;
Table 1), resulting in a .170-fold increase in CAZ hydrolysis,
similar to a previous report [15]. Isolates MSHRs 1141 and 1225
contained penA
+, whereas isolates subsequently collected from
P337 (Table 1), with the exception of MSHR 1226, contained
both penA -21A and penA 281A mutations. The dual-mutant penA
isolates from P337 also yielded CAZ MICs of $256 mg/mL.
Interestingly, MSHR 1226, an isolate collected mid-infection,
contained only the penA 281A mutation and not the promoter
region - 21A SNP.
Comparison of native and heterologous expression of
penA variants
We used a heterologous cloning and expression approach to
better understand the link between penA mutations, CAZ
R and
substrate specificity and compared these data with penA behavior
in the native host, as a previous study has demonstrated that
heterologous hosts can be useful for approximating the activity
of B. pseudomallei PenA towards b-lactam substrates [13]. We
used an E. cloni system to express penA amplified from MSHRs
99 (-21A mutant), 1226 (281A mutant) and 1300 (-21A and
281A dual mutant) and a CAZ
S penA+ control strain (MSHR
663). MICs of the E. cloni host were compared to E. cloni
expressing the penA variants to determine background CAZ
hydrolysis (Table 2).
Neither the heterologously expressed PenA
+ or the -21A penA
mutant altered the CAZ MIC in E. cloni despite a 16-fold increase
in CAZ MIC in B. pseudomallei -21A penA, indicating lowered
sensitivity of the heterologous system. MSHR 1226 penA
(containing the 281A mutation) increased degradation of CAZ
by 8-fold and MSHR 1300 (dual penA mutant) by 16-fold, which
mimicked the increases observed in the native B. pseudomallei host,
albeit with substantially lower fold differences. Interestingly,
increased activity towards CAZ by both the dual and C69Y-
mutated PenA mutants was accompanied by a decrease in
hydrolytic activity for amoxicillin (AMX), and to a lesser extent
ampicillin (AMP) (Table 2). In contrast, we saw an increase in
MICs in penA -21A against a range of b-lactams. This
phenomenon was most evident when comparing AMX MICs,
where E. cloni expressing penA -21A yielded a 1.5-fold increase
compared with penA
+.I nB. pseudomallei, both penA -21A and penA
+
gave AMX MICs of $256 mg/mL, indicating that higher MIC
detection would be required to confirm these heterologous AMX
MIC differences in the native host. These results demonstrate that
the amino acid mutation in PenA is highly favorable for CAZ
hydrolysis but causes a substantial reduction in hydrolytic activity
towards at least two other b-lactams, as previously shown [15].
The penA -21A mutant mutation also enhances hydrolysis of CAZ,
although not to the level of the C69Y mutant. However, penA -21A
causes upregulation of penA, which enhances hydrolysis towards
other b-lactam substrates, including antibiotics containing clavu-
lanic acid.
Knockout and complementation of penA
Following confirmation of CAZ
R by heterologous expression of
penA, this gene was removed from mutant and w.t. B. pseudomallei
strains (CAZ
R MSHR 99, CAZ
S MSHR 1141 and CAZ
R MSHRs
1226 and 1300) to determine CAZ MICs in the original host
compared with its penA knockout. Following penA removal, we
screened for CAZ MICs in penA knockouts. All DpenA strains
possessed a CAZ
S phenotype, with MICs of approximately 1 mg/
mL (Table 2). To further verify the role of penA in CAZ
R,w e
complemented all strains with penA
+ to test for restoration of wild-
type CAZ
S and AMX
R phenotypes. Finally, we reinserted the
original penA genes back into CAZ
R strains to examine
reproducibility of CAZ
R phenotypes (Table 2). When penA
+ was
introduced into the MSHR 99, MSHR 1226 or MSHR 1300
Burkholderia pseudomallei Ceftazidime Resistance
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indicating that these mutations were the sole cause of CAZ
R in
these strains. Further evidence of a single-gene phenotype was
confirmed following restoration of the CAZ
R MICs in CAZ
R
strains complemented with their native penA (Table 2).
Prevalence of penA mutants in Burkholderia spp.
Once it was established that penA 281A and penA -21A were
responsible for conferring CAZ
R in the B. pseudomallei strains from
our study, we determined the frequency of these mutations across
clinical and environmental Burkholderia isolates. We obtained the
most robust allelic discrimination using the SYBR MAMA format
(Figure S1). Following verification of assay performance, the penA
SYBR MAMA assays were screened across approximately 2400
Burkholderia spp. isolates derived from clinical and environmental
sources. Screening for these mutations across our Burkholderia DNA
collection revealed that only MSHR 1226, 1298, 1300 and 1302,
all isolates from P337, contained the mutant penA 281A allele. In
contrast, we identified two additional isolates carrying the penA -
21A mutation. One isolate was from a clinical case in Malaysia
and the second was an environmental isolate from undisturbed soil
in Northeast Thailand.
Clonality of P21 and P337 infection
We were interested in determining if the isolates obtained from
P21 and P337 were clonal, suggestive of a relapsed infection and in
vivo development of CAZ
R rather than re-infection with a different
CAZ
R strain. To determine the clonality of infection, we carried
out 22-locus MLVA [24] on the nine isolates from the two
patients. MLVA targets rapidly mutable loci throughout the
genome; therefore, unrelated isolates are highly likely to display
distinct MLVA profiles, making this method indispensable for
determining in vivo infection clonality [24,27].
In P21, MLVA failed to show any variability among the three
strains across all 22-loci. In P337, MLVA demonstrated 12
mutations among all six strains, ranging from a two-repeat
insertion to a five-repeat deletion (data not shown). These
mutation rates are within the realm of expected in vivo mutation
rates of clonal B. pseudomallei isolates within a single host, as
determined in previous studies [24,27]. Further, there was no
evidence of a temporal distinction between MLVA mutants, with
mutations occurring across all timepoints (data not shown).
MLST was also performed on the patient isolates to consolidate
our conclusion of clonality from the MLVA profiles. As expected,
MLST genotypes were identical within patients, with P21 isolates
Table 2. MICs of B. pseudomallei isolates with and without penA and heterologously expressed genes in ‘‘E. cloni’’.
Bacterial strain b-lactam
a,b
CAZ AMP AMX AMC CRO CEC CLA CT-CTL MEPM
E. cloni pGC - no insert 0.25 2 8 2 0.13 2 0.19 ,0.25/0.064 0.023
E. cloni pGC-penA
+ 0.25–0.5 12 24 4 1.5 6 0.19 ,0.25/0.094 0.023
E. cloni pGC-penA -21A 0.25–0.5 16 36 5 1.5 6 0.19 ,0.25/0.125 0.023
E. cloni pGC-penA 281A 3–4 2 8 4 0.5 4 0.19 0.25/0.125 ND
E. cloni pGC-penA -21A, 281A (dual mutant) 8 2 8 2 0.75 2 0.19 ,0.25/0.125 0.023
Burkholderia pseudomallei
MSHR 73 (penA
+) 1.5 24 $256 1.5 16 $256 1.5 .16/.11
MSHR 95 (penA
+) 1.5 24 $256 1.5 12 $256 1.5 .16/.11
MSHR 99 (penA -21A) 16 $256 $256 8 $256 $256 .4 .16/.11 . 5
MSHR 99 DpenA 1 2 3 1.5 1.5 48 1 2/.1N D
MSHR 99 penA -21A (cis complement) 16 $256 $256 12 $256 $256 .4 .16/.1N D
MSHR 99 penA
+ (cis complement) 2 16 192–256 2 16 $256 1.5 .16/.1N D
MSHR 1225 (penA
+)1 8 $256 1.5 8 $256 0.75 .16/.1N D
MSHR 1298 (penA -21A, 281A) (dual mutant) $256 8 32 1.5 $256 $256 4 .16/.1N D
MSHR 1302 (penA -21A, 281A) (dual mutant) $256 8 32 1.5 $256 $256 4 .16/.1N D
MSHR 1141 (penA
+) 1.5 24 $256 1.5 8 $256 0.75 .16/.1N D
MSHR 1141 DpenA 1 2 4 1.5 1.5 24 0.75 .16/.1N D
MSHR 1141 penA
+ (cis complement) 1.5 24 $256 1.5 8 $256 0.75 .16/.1N D
MSHR 1226 (penA 281A) $256 3 12 2 96 $256 3 .16/.1N D
MSHR 1226 DpenA 1 1.5 4 1.5 1 16 0.75 1/.1N D
MSHR 1226 penA 281A (cis complement) $256 ND ND ND ND ND ND ND ND
MSHR 1226 penA
+ (cis complement) 2 24 $256 2 16 $256 3 .16/.1N D
MSHR 1300 (penA -21A, 281A) $256 8 32 1.5 $256 $256 3 .16/.14
MSHR 1300 DpenA 0.5 1.5 3 1 0.75 16 0.75 1.5/.14
MSHR 1300 penA
+ (cis complement) 2 12 192–256 1.5 8 $256 0.75 .16/.1N D
MSHR 1300 penA -21A, 281A (cis complement) $256 8 24 1.5 $256 $256 2–3 .16/.1N D
aCAZ, ceftazidime; AMX, Amoxicillin; AMP, Ampicillin; AMC, Amoxicillin-clavulanic acid; CRO, ceftriaxone; CEC, cefaclor; CLA, ceftazidime-clavulanic acid; CT-CTL,
cefotaxime/cefotaxime-clavulanic acid; MEPM, meropenem; ND, not determined.
bMICs presented in mg/mL.
doi:10.1371/journal.pone.0030789.t002
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330. These results are unsurprising as infection relapse is more
common than re-infection [28–30].
Discussion
Melioidosis is a serious disease without an effective vaccine that
requires prolonged antibiotic therapy to eradicate. Due to the
intrinsic resistance of B. pseudomallei to a wide range of antibiotics,
the treatment options for melioidosis are unfortunately limited to a
small number of antimicrobial agents. Primary treatment usually
consists of IV CAZ followed by prolonged oral antibiotic therapy
with a secondary drug such as trimethoprim-sulfamethoxazole,
doxycycline or AMC [11]. Although primary resistance to these
clinical drugs is rare [4], development of resistance can result as a
consequence of the prolonged therapy typically needed for treating
melioidosis, especially in cases of recurrent melioidosis, which
afflicts approximately 10% of patients [31]. Due to the heavy
reliance on CAZ as first line therapy for melioidosis, both primary
and secondary CAZ
R pose a significant challenge in treatment and
play a critical role in patient outcomes.
Most cases of melioidosis are treated with IV CAZ monother-
apy in the initial eradication phase, followed by a change in
antimicrobial drugs once the patient starts oral therapy. The
switch in treatment probably abrogates the selective pressure on
CAZ
R mutants to arise and become dominant in vivo. However,
clinicians may employ CAZ multiple times or for an extended
length during the course of melioidosis, particularly in recurrent
cases, a strategy that leads to an increased potential for CAZ
R to
develop. In the current study, we observed B. pseudomallei develop
both low-level and high-level CAZ
R in direct response to
chemotherapy with CAZ in two separate cases of recurrent
melioidosis. Both patients suffered relapse within months of initial
infection and were treated with IV CAZ as the primary treatment
in both instances. In the first patient, P21, B. pseudomallei evolved
low-level resistance due to a SNP located -21 bp upstream of the
putative penA start codon, which resulted in an approximate 10-
fold up-regulation of the class A b-lactamase PenA. This promoter
mutation caused resistance to not only the first line treatment,
CAZ, but alarmingly, the follow-up AMC chemotherapy. In the
second patient, P337, high-level CAZ
R developed due primarily to
an amino acid substitution in PenA that altered the substrate
specificity of this enzyme, increasing CAZ
R by at least 170-fold.
Interestingly, the same promoter mutation altering PenA expres-
sion was also observed in many isolates from P337, suggesting
continued selection pressure for increased penA expression. We
strongly suspect that the repeated treatment with CAZ in these
relapsed melioidosis patients likely provided the prolonged
selective pressure needed for CAZ
R mutations to develop and
become dominant within the in vivo bacterial population. Although
more recurrent melioidosis cases would need to be investigated to
confirm this hypothesis, our study demonstrates that there is a risk
for treatment failure associated with repeated CAZ chemotherapy
in relapsing melioidosis patients that is worthy of further study.
Although high-level CAZ
R is very uncommon in B. pseudomallei,
it has been previously reported. Sam and colleagues [14] isolated a
CAZ
R strain (24 mg/mL) from a patient who later harbored B.
pseudomallei with high-level CAZ
R ($256 mg/mL), indicating a
potential stepwise mutation progression in CAZ
R. In the current
study, we did not detect a low-level CAZ
R isolate from P337 (all
isolates obtained over the course of infection were either CAZ
S or
showed high-level CAZ
R), suggesting that the single penA 281A
mutation (C69Y) was responsible for the high-level resistance
phenotype. Alteration of this amino acid yielded a CAZ
R MIC of
$256 mg/mL in a Select Agent exempt strain of B. pseudomallei
[15]. Our study confirmed these previous results based on isolate
MSHR 1226, which contained this single mutation and was
resistant to CAZ at $256 mg/mL. However, the small sample size
(n=6) used in the current study renders the possibility that the low-
level CAZ
R phenotype was missed during sampling. In addition,
Sam and co-workers [14] saw an increased resistance to AMC for
their initial isolates that we did not identify in P337. However, we
observed a similar resistance profile towards other b-lactams in the
P21 isolate, MSHR 99. It is interesting to speculate whether the
initial isolates from the Sam et al. study possessed an alteration in
the penA promoter region, similarly to MSHR 99, as the MIC
values for both AMC and CAZ are identical between studies.
Having demonstrated both heterologously and in the native host
that the 281A and -21A penA mutants were responsible for CAZ
R
in these isolates, we were interested in determining the frequency
of these mutations over a large collection of B. pseudomallei from
both clinical and environmental origins. PCR screening of over
2400 samples (of which none are known to be from other recurrent
melioidosis patients) showed that no other isolates with the PenA
C69Y mutation were found, indicating that this mutation is
fortunately rare. We propose several reasons for the low frequency
of C69Y in B. pseudomallei. First, B. pseudomallei is a soil dwelling
organism, yet CAZ is a synthetically manufactured antibiotic that
does not naturally occur in the environment [32] and thus there is
no selection pressure to develop CAZ
R in the environment.
Second, multiple molecular mechanisms likely exist for generating
CAZ
R in Burkholderia spp. [13,14]. Third, there appears to be a
trade-off for high-level resistance to CAZ in the form of increased
susceptibility to the other b-lactams (Table 2), which provides a
heavy selective disadvantage to B. pseudomallei in the face of b-
lactamases produced by other soil-borne microbes. In other words,
the penA281A mutation is only favorable to B. pseudomallei during
an in vivo infection that includes CAZ as a chemotherapeutic agent.
Unlike penA281A, our screening efforts did identify two
additional isolates with the penA -21A mutation, totaling
approximately 0.1% prevalence within our B. pseudomallei collec-
tion. One of these mutants belonged to a Malaysian melioidosis
case. We lack clinical data on this patient so cannot determine
whether this adaptation was acquired in vivo and as a result of
treatment with CAZ. The penA -21A mutation was not restricted to
clinical isolates, being found in an environmental sample from an
undisturbed soil location in Northeast Thailand. Unlike penA281A,
the penA -21A mutation caused cross-resistance to all the b-lactams
tested, including AMC, which contains a b-lactamase inhibitor.
The infrequency of both penA mutations identified in this study
supports the continued usefulness of CAZ as a first line treatment
option for melioidosis. However, caution should be exercised when
administering any antibiotic to melioidosis patients, particularly in
light of our study. Ideally, clinicians should ascertain the MIC
status of strains during the course of treatment and adjust therapy
accordingly. In particular, B. pseudomallei strains that possess low-
level CAZ
R, such as the P21 penA -21A mutants, can result in
treatment failure to other b-lactams, including those that contain
b-lactamase inhibitors. Alternately, treatment with CAZ can
supply sufficient selective pressure for B. pseudomallei to develop
high-level CAZ
R, as observed in P337.
The system of heterologous cloning and expression used in our
study has been important in expediting the identification of genes
responsible for antibiotic resistance. Due to the Select Agent
classification of B. pseudomallei, genetic manipulation is often highly
laborious and the number of genetic tools available to researchers
is limited. Using DNA derived from B. pseudomallei and a Biosafety
Level 1 heterologous screening host (such as E. coli K-12) has
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resistance than would otherwise be possible working with the
native hosts. However, a secondary method for candidate gene
identification, such as allelic exchange, is still required to verify
heterologous expression results as expression profiles can vary
markedly between the heterologous and native bacteria. For
instance, G+C content, codon usage, alterations in expression
levels from non-native promoters or vector copy numbers,
differences in protein folding or other post-translational modifica-
tions can result in changes of native function, leading to erroneous
expression results [33,34]. A recent study describes the approval
and use of a Select Agent exempt strain of B. pseudomallei as a
heterologous host for virulent B. pseudomallei counterparts [15].
This new strain will enable researchers to rapidly identify single
gene candidates and allow multiple gene, random cloning
approaches to be undertaken, greatly accelerating functional
genomics of B. pseudomallei.
In conclusion, we have demonstrated that antibiotic adminis-
tration in cases of chronic and recurrent bacterial infections can
have a profound impact on treatment efficacy. We provide
functional evidence for direct selection of B. pseudomallei mutants
with enhanced antibiotic resistance following administration of the
first line of defense, CAZ, and for one patient, both the first and
second lines of defense (CAZ and AMC). Sufficient information
regarding mechanisms of resistance and the development of robust
PCR assays will one day allow clinicians to monitor bacterial
populations in real-time, with alteration of treatment as bacterial
populations are identified that develop or alter their resistance
profiles. We have shown that although B. pseudomallei is able to
develop high-level CAZ
R it does so infrequently and at the cost of
becoming more sensitive to other antimicrobials, providing an
avenue for future research in combating recurrent and chronic
melioidosis. Other potential mechanisms of CAZ
R in B.
pseudomallei, such as efflux pumps, alterations in other b-lactamases
or changes in the cell wall, remain to be characterized. Elucidation
of these resistance mechanisms will allow rapid characterization of
a B. pseudomallei infection and appropriate treatment to be
administered, reducing the morbidity and mortality of melioidosis.
Supporting Information
Figure S1 B. pseudomallei real-time SYBR MAMA penA
281A SNP assay. The left real-time PCR amplification plot
demonstrates preferential amplification of penA
+ in a non-mutated
B. pseudomallei strain (K96243), whereas the right amplification plot
shows the mutant polymorphism (penA 281A) from B. pseudomallei
MSHR 1300. Blue, penA
+; red, mutant penA 281A allele; green, no-
template controls.
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